Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
CHRS's Cash to Debt is ranked higher than
90% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. CHRS: No Debt )
CHRS' s 10-Year Cash to Debt Range
Min: 9.41   Max: No Debt
Current: No Debt

Equity to Asset 0.36
CHRS's Equity to Asset is ranked higher than
57% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CHRS: 0.36 )
CHRS' s 10-Year Equity to Asset Range
Min: -2.05   Max: 0.36
Current: 0.36

-2.05
0.36
Z-Score: 4.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -632.50
CHRS's Operating margin (%) is ranked higher than
59% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. CHRS: -632.50 )
CHRS' s 10-Year Operating margin (%) Range
Min: -2028.33   Max: -207.94
Current: -632.5

-2028.33
-207.94
Net-margin (%) -700.95
CHRS's Net-margin (%) is ranked higher than
59% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. CHRS: -700.95 )
CHRS' s 10-Year Net-margin (%) Range
Min: -1949.65   Max: -280.12
Current: -700.95

-1949.65
-280.12
ROE (%) -77.61
CHRS's ROE (%) is ranked higher than
59% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. CHRS: -77.61 )
CHRS' s 10-Year ROE (%) Range
Min: 0   Max: 0
Current: -77.61

ROA (%) -23.93
CHRS's ROA (%) is ranked higher than
72% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. CHRS: -23.93 )
CHRS' s 10-Year ROA (%) Range
Min: -145   Max: -74.26
Current: -23.93

-145
-74.26
ROC (Joel Greenblatt) (%) -767.50
CHRS's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. CHRS: -767.50 )
CHRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4130.01   Max: -2081.48
Current: -767.5

-4130.01
-2081.48
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 22.80
CHRS's P/B is ranked lower than
58% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. CHRS: 22.80 )
CHRS' s 10-Year P/B Range
Min: 6.35   Max: 22.8
Current: 22.8

6.35
22.8
P/S 6.10
CHRS's P/S is ranked higher than
82% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. CHRS: 6.10 )
CHRS' s 10-Year P/S Range
Min: 3.36   Max: 8.31
Current: 6.1

3.36
8.31
EV-to-EBIT -10.26
CHRS's EV-to-EBIT is ranked higher than
65% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CHRS: -10.26 )
CHRS' s 10-Year EV-to-EBIT Range
Min: -1.7   Max: 0.7
Current: -10.26

-1.7
0.7
Current Ratio 3.46
CHRS's Current Ratio is ranked higher than
69% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CHRS: 3.46 )
CHRS' s 10-Year Current Ratio Range
Min: 0.85   Max: 3.46
Current: 3.46

0.85
3.46
Quick Ratio 3.46
CHRS's Quick Ratio is ranked higher than
70% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CHRS: 3.46 )
CHRS' s 10-Year Quick Ratio Range
Min: 0.85   Max: 3.46
Current: 3.46

0.85
3.46
Days Sales Outstanding 126.59
CHRS's Days Sales Outstanding is ranked higher than
74% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. CHRS: 126.59 )
CHRS' s 10-Year Days Sales Outstanding Range
Min: 28.36   Max: 36.88
Current: 126.59

28.36
36.88

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.10
CHRS's Price/Net Cash is ranked higher than
62% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. CHRS: 28.10 )
CHRS' s 10-Year Price/Net Cash Range
Min: 18.13   Max: 18.13
Current: 28.1

Price/Net Current Asset Value 26.30
CHRS's Price/Net Current Asset Value is ranked higher than
59% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. CHRS: 26.30 )
CHRS' s 10-Year Price/Net Current Asset Value Range
Min: 9.22   Max: 9.22
Current: 26.3

Price/Tangible Book 24.50
CHRS's Price/Tangible Book is ranked lower than
58% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. CHRS: 24.50 )
CHRS' s 10-Year Price/Tangible Book Range
Min: 0   Max: 0
Current: 24.5

Price/Median PS Value 1.10
CHRS's Price/Median PS Value is ranked higher than
84% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. CHRS: 1.10 )
CHRS' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 0.69
Current: 1.1

Earnings Yield (Greenblatt) -9.30
CHRS's Earnings Yield (Greenblatt) is ranked higher than
57% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CHRS: -9.30 )
CHRS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -13   Max: 0
Current: -9.3

-13
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
COHERUS BIOSCIENCES, INC. Financials May 19 2015
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results May 11 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other... May 11 2015
Coherus BioSciences Inc Earnings Call scheduled for 4:30 pm ET today May 11 2015
Coherus BioSciences Reports First Quarter 2015 Financial and Operating Results May 11 2015
Coherus BioSciences to Report First Quarter 2015 Financial Results on May 11 May 04 2015
Coherus BioSciences to Report First Quarter 2015 Financial Results on May 11 May 04 2015
Coherus BioSciences to Present at Deutsche Bank Health Care Conference on May 7 Apr 30 2015
Coherus BioSciences to Present at Deutsche Bank Health Care Conference on May 7 Apr 30 2015
Baxter (BAX) Beats Q1 Earnings Estimates, Sales Down Y/Y - Analyst Blog Apr 24 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events Apr 17 2015
Baxter Amends Financial Provisions of Coherus Collaboration - Analyst Blog Apr 16 2015
Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement Apr 15 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Apr 15 2015
Coherus BioSciences and Baxter Announce Amendment to Etanercept Biosimilar Collaboration Agreement Apr 15 2015
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Apr 14 2015
Fidelity CEO taps personal fortune for bets on cancer-related IPOs Apr 09 2015
Weakness Seen in Coherus Biosciences (CHRS): Stock Tumbles 10.8% - Tale of the Tape Apr 02 2015
Biotechs Raising New Capital in Droves Apr 01 2015
Coherus Prices Upsized Public Offering of $120.0 Million of Common Stock Mar 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK